Laboratorios Richmond SACIF Market Cap ($66.97 Million)
Market Cap & Net Worth: Laboratorios Richmond SACIF (RICH)
Laboratorios Richmond SACIF market cap. Laboratorios Richmond SACIF (BA:RICH) has a market capitalization of $66.97 Million (AR$92.55 Billion) as of November 8, 2026. Listed on the BA stock exchange, this Argentina-based company holds position #20523 globally and #56 in its home market, demonstrating a 6.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Laboratorios Richmond SACIF's stock price AR$1390.00 by its total outstanding shares 66584323 (66.58 Million). Also see RICH cash flow conversion for how efficiently the company converts equity into cash flow.
Laboratorios Richmond SACIF Market Cap History (2017–2026)
Laboratorios Richmond SACIF market cap history from 2017 to 2026. Data shows growth from $1.51 Million to $66.97 Million (53.87% CAGR). Check Laboratorios Richmond SACIF (RICH) stock price for real-time trading data and today's change.
Laboratorios Richmond SACIF Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Laboratorios Richmond SACIF's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Laboratorios Richmond SACIF growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Laboratorios Richmond SACIF's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Laboratorios Richmond SACIF's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.51 Million | $982.22 Million | $40.76 Million | 0.00x | 0.04x |
| 2018 | $1.75 Million | $1.82 Billion | -$215.60 Million | 0.00x | N/A |
| 2019 | $5.58 Million | $3.90 Billion | $116.44 Million | 0.00x | 0.05x |
| 2020 | $5.55 Million | $6.18 Billion | $486.24 Million | 0.00x | 0.01x |
| 2021 | $10.70 Million | $16.62 Billion | $591.46 Million | 0.00x | 0.02x |
| 2022 | $18.74 Million | $18.47 Billion | $163.43 Million | 0.00x | 0.11x |
| 2023 | $33.73 Million | $84.99 Billion | -$23.63 Billion | 0.00x | N/A |
| 2024 | $86.48 Million | $91.79 Billion | $23.85 Billion | 0.00x | 0.00x |
Competitor Companies of RICH by Market Capitalization
Companies near Laboratorios Richmond SACIF in the global market cap rankings as of November 8, 2026. Also see Laboratorios Richmond SACIF total assets for a full breakdown of the balance sheet.
Key companies related to Laboratorios Richmond SACIF by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Laboratorios Richmond SACIF (2017–2026)
Market capitalization of Laboratorios Richmond SACIF from 2017 to today. Between 2017 and today, Laboratorios Richmond SACIF's market cap moved from $1.51 Million to $ 66.97 Million, with a yearly change of 53.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AR$66.97 Million | -28.72% |
| 2025 | AR$93.95 Million | +8.64% |
| 2024 | AR$86.48 Million | +156.43% |
| 2023 | AR$33.73 Million | +79.95% |
| 2022 | AR$18.74 Million | +75.23% |
| 2021 | AR$10.70 Million | +92.63% |
| 2020 | AR$5.55 Million | -0.43% |
| 2019 | AR$5.58 Million | +219.56% |
| 2018 | AR$1.75 Million | +15.73% |
| 2017 | AR$1.51 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Laboratorios Richmond SACIF was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $66.97 Million USD |
| MoneyControl | $66.97 Million USD |
| MarketWatch | $66.97 Million USD |
| marketcap.company | $66.97 Million USD |
| Reuters | $66.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more